Playback speed
10 seconds
Lecture Summary - ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab Stratified to Tumor Mutation Burden for High-Risk Stage 2/3 Deficient-MMR/MSI-H CRC
By
ASCO 2022 Conference Coverage
FEATURING
Kai-Keen Shiu
By
ASCO 2022 Conference Coverage
FEATURING
Kai-Keen Shiu
36 views
June 9, 2022
Comments 0
Login to view comments.
Click here to Login